Meeting
2022 ASCO Annual Meeting
CCTG PR21: A randomized phase II study of [177lu]lu-PSMA-617 verus docetaxel in patients with metastatic castration-resistant prostate cancer and PSMA-positive disease (NCT04663997).
Authors
Kim N. Chi
BC Cancer Agency, University of British Columbia, Vancouver, BC, Canada
Kim N. Chi , Fred Saad , Wendy R. Parulekar , Urban Emmenegger , Sebastien J. Hotte , Frederic Pouliot , Glenn Bauman , Katherine A. Zukotynski , Stuart Peacock , Alexander William Wyatt , Jean-Mathieu Beauregard , Justin Lee , Carlos Uribe , Conor Dellar , Keyue Ding , Francois Benard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04663997
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS5110)
DOI
10.1200/JCO.2022.40.16_suppl.TPS5110
Abstract #
TPS5110
Poster Bd #
284b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: Evan Y. Yu
Poster
2020 ASCO Virtual Scientific Program
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
First Author: Atish Dipankar Choudhury
Poster
2020 Genitourinary Cancers Symposium
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: Evan Y. Yu
Poster
2020 Genitourinary Cancers Symposium
A phase II study of M6620 in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.
First Author: Atish Dipankar Choudhury